Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study

被引:1
|
作者
Cong, Duanduan [1 ]
Song, Jie [2 ]
Liu, Yue [1 ]
Tan, Yan [2 ]
Xue, Wei [1 ]
Liu, Xiaohui [1 ]
Qi, Wenyuan [1 ]
Lu, Jun [2 ]
Yuan, Xiaojuan [3 ]
Zhou, Yongchun [3 ]
Hui, Ai-Min [2 ]
Li, Kexin [1 ]
机构
[1] Chinese Acad Med Sci, Clin Trial Ctr, Beijing Hosp, Natl Ctr Gerontol,Inst Geriatr Med,Assessment Cli, 1 Dahua Rd, Beijing 100005, Peoples R China
[2] Shanghai Fosun Pharmaceut Dev Co Ltd, Clin Res Dept, Shanghai 200000, Peoples R China
[3] Wanbang Biopharmaceut Co Ltd, Xuzhou, Jiangsu, Peoples R China
关键词
Clinical trial; COMT inhibitor; Ethnicity; Opicapone; Pharmacodynamics; Pharmacokinetics; Tolerability; CATECHOL-O-METHYLTRANSFERASE; PARKINSONS-DISEASE; MOTOR FLUCTUATIONS; LEVODOPA; INHIBITORS; DISCOVERY; THERAPY; ADJUNCT; LIVER;
D O I
10.1007/s40120-021-00314-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction This study evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of opicapone (OPC) in healthy Chinese and Caucasian subjects. Methods In this open-label, single-center, phase 1 study, eligible Chinese subjects received one of three OPC doses (25, 50, or 100 mg), and Caucasian subjects received either 25 or 50 mg of OPC. All subjects were administered a single dose of OPC, whereas subjects in the 50-mg OPC group continued to receive once-daily doses of 50 mg OPC for 10 days. The primary endpoint was to evaluate and compare the plasma concentrations and PK parameters of OPC and its main metabolite, and erythrocyte-soluble catechol-O-methyltransferase (S-COMT) activity in Chinese subjects with that of Caucasian subjects. The secondary endpoint was to evaluate the safety of OPC in Chinese subjects. The estimated results for geometric mean ratios (GMRs) were evaluated with the standard bioequivalence (BE) limits between 80% and 125% to evaluate the ethnic differences. All statistical analyses were performed using SAS version 9.4. Results In total, 70 subjects (45 Chinese, 25 Caucasian) were enrolled; the majority of them were male (85.7%). The plasma exposure of both OPC and BIA 9-1103 increased in an approximately dose-proportional manner in both populations. Maximum S-COMT inhibition ranged from 79% to 95% after a single dose and was about 94% after a 10-day once-daily regimen in both populations. The point estimates of GMRs (Chinese/Caucasian) and 90% CI, except C-max in 25-mg and 50-mg OPC groups, for PK and PD parameters were within 80% to 125%. Furthermore, no new risks or safety concerns associated with OPC were identified, indicating a tolerable safety profile in healthy Chinese subjects. Conclusion Ethnicity had no significant impact on PK and PD parameters after single or multiple doses of OPC, and OPC was safe and tolerable in healthy Chinese subjects.
引用
收藏
页码:283 / 301
页数:19
相关论文
共 50 条
  • [41] Pharmacokinetics and Tolerability of Intravenous Metadoxine in Healthy Chinese Volunteers: a Randomized, Open-Label, Single-and Multiple-Dose Study
    Zhao, Hengli
    Cao, Ruoming
    Fang, Zengjun
    Wang, Haisheng
    LATIN AMERICAN JOURNAL OF PHARMACY, 2018, 37 (07): : 1361 - 1365
  • [42] Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial
    Hu, Chaoying
    Jia, Jingying
    Dong, Kelly
    Luo, Linda
    Wu, Kai
    Mehta, Rashmi
    Peng, Jack
    Ren, Yan
    Gross, Annette
    Yu, Hui
    PLOS ONE, 2015, 10 (03):
  • [43] A Single-center, Open-label, Parallel Control Study Comparing the Pharmacokinetics and Safety of a Single Oral Dose of Roflumilast and Its Active Metabolite Roflumilast N-oxide in Healthy Chinese and Caucasian Volunteers
    Han, Mai
    Lin, Xiao-Yan
    Cui, Gang
    Chen, Shuai
    Wu, Wei
    Mi, Na
    Wang, Jing
    Xiao, Chun-Yan
    Zhang, Xin
    Lu, Xing
    Li, Jin-Tong
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (03): : 314 - 323
  • [44] Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects
    Yue-Qi Li
    Zheng-Yu Yan
    Hong-Wen Zhang
    Lu-Ning Sun
    Hui-Wen Jiao
    Mei-Feng Wang
    Li-Yuan Yu
    Lei Yu
    Zi-Qing-Yun Yuan
    Ling Meng
    Yong-Qing Wang
    European Journal of Clinical Pharmacology, 2017, 73 : 547 - 554
  • [45] Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects
    Li, Yue-Qi
    Yan, Zheng-Yu
    Zhang, Hong-Wen
    Sun, Lu-Ning
    Jiao, Hui-Wen
    Wang, Mei-Feng
    Yu, Li-Yuan
    Yu, Lei
    Yuan, Zi-Qing-Yun
    Meng, Ling
    Wang, Yong-Qing
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (05) : 547 - 554
  • [46] Pharmacokinetics and Tolerability of Tenofovir Disoproxil Fumarate 300 mg Once Daily: An Open-Label, Single- and Multiple-Dose Study in Healthy Chinese Subjects
    Hu, Chao-ying
    Liu, Yan-mei
    Liu, Yun
    Chen, Qian
    Wang, Wei
    Wu, Kai
    Dong, Jie
    Li, Jie
    Jia, Jing-ying
    Lu, Chuan
    Sun, Shi-xuan
    Yu, Chen
    Li, Xuening
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1884 - 1889
  • [47] A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
    Sheng Feng
    Ji Jiang
    Pei Hu
    Jian-yan Zhang
    Tao Liu
    Qian Zhao
    Bi-lu Li
    Acta Pharmacologica Sinica, 2012, 33 : 1353 - 1358
  • [48] A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
    Feng, Sheng
    Jiang, Ji
    Hu, Pei
    Zhang, Jian-yan
    Liu, Tao
    Zhao, Qian
    Li, Bi-lu
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (11) : 1353 - 1358
  • [49] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
    Daniela Willen
    Wolfgang Uhl
    Peter Wolna
    Orestis Papasouliotis
    Özkan Yalkinoglu
    European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45 : 27 - 40
  • [50] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
    Willen, Daniela
    Uhl, Wolfgang
    Wolna, Peter
    Papasouliotis, Orestis
    Yalkinoglu, Oezkan
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45 (01) : 27 - 40